SBIR/STTR Research Award
A Totally Synthetic Immunostimulator that Targets Toll-like Receptor 2 and NOD2: Toward Improved Influenza Vaccines
Award amount
$243,000Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Centers for Disease Control and Prevention
- Recipient company
- TEICHOS LABORATORIES, LLC
- Proposal award date
- 2021-09-30
- Contract end date
- 2022-09-29
- UEI
- UGFLPLUM9UP5
- Solicitation number
- PA20-260
- Topic code
- NCIRD
Research abstract
ABSTRACT: Teichos technology, amacromolecularplatformofpeptidoglycanbiologics(sPGN)producedbyproprietary chemoenzymatictotalsynthesis,offersimprovedinfluenzavaccinesthroughsignificantlyimprovedadjuvant performance. TL-001, a stimulatory sPGN, demonstrated adjuvant activity at low doses in standard laboratory vaccination model. We propose to evaluate TL-001 for its potential utility as an influenza vaccine adjuvant by confirming its mechanism of action in monocyte and macrophage cultures and its ability to enhance antibody and T cell responses using an influenza H1 subunit vaccination model in mice.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- TEICHOS LABORATORIES, LLC. ""AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT"".
- Immunotherapy for Factor VIII Inhibition in Hemophilia A
- AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH ANOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines
- Rapid SARS-CoV-2 Spike Protein Neutralizing Antibody Tests for Evaluating COVID Vaccine-Generated Immunity
- Development of Antigen-based Vertical Flow Assay for the Rapid Detection of SARS-CoV-2, Influenza A/B, and RSV
- Rapid mass production of human influenza vaccine in insects using genome editing
- Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus
Research funding history
4 SBIR/STTR records share this UEI (2021–2023). Reported award amounts total $1,102,613. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services